218 related articles for article (PubMed ID: 26494109)
1. Genetic and functional characterization of HIV-1 Vif on APOBEC3G degradation: First report of emergence of B/C recombinants from North India.
Ronsard L; Raja R; Panwar V; Saini S; Mohankumar K; Sridharan S; Padmapriya R; Chaudhuri S; Ramachandran VG; Banerjea AC
Sci Rep; 2015 Oct; 5():15438. PubMed ID: 26494109
[TBL] [Abstract][Full Text] [Related]
2. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
3. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
4. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
5. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.
Iwabu Y; Kinomoto M; Tatsumi M; Fujita H; Shimura M; Tanaka Y; Ishizaka Y; Nolan D; Mallal S; Sata T; Tokunaga K
J Biol Chem; 2010 Nov; 285(46):35350-8. PubMed ID: 20833716
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
Infect Genet Evol; 2011 Aug; 11(6):1256-62. PubMed ID: 21571098
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Vif protein sequence variations in South African people living with HIV and their influence on Vif-APOBEC3G interaction.
Williams ME
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):325-338. PubMed ID: 38072879
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
[TBL] [Abstract][Full Text] [Related]
9. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
11. C-terminal half of HIV-1 Vif C possesses major determinant for APOBEC3G degradation.
Gupta N; Banerjea AC
AIDS; 2009 Jan; 23(1):141-3. PubMed ID: 19050398
[No Abstract] [Full Text] [Related]
12. [Progress in the study of HIV-1 Vif and related inhibitors].
Li ZY; Zhan P; Liu XY
Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
[TBL] [Abstract][Full Text] [Related]
13. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
14. Hydrodynamic and functional analysis of HIV-1 Vif oligomerization.
Techtmann SM; Ghirlando R; Kao S; Strebel K; Maynard EL
Biochemistry; 2012 Mar; 51(10):2078-86. PubMed ID: 22369580
[TBL] [Abstract][Full Text] [Related]
15. Mutation Vif-22H, which allows HIV-1 to use the APOBEC3G hypermutation to develop resistance, could appear more quickly in certain non-B variants.
Yebra G; Holguín A
J Antimicrob Chemother; 2011 Apr; 66(4):941-2. PubMed ID: 21393191
[No Abstract] [Full Text] [Related]
16. Rapid evolution of primate antiviral enzyme APOBEC3G.
Zhang J; Webb DM
Hum Mol Genet; 2004 Aug; 13(16):1785-91. PubMed ID: 15198990
[TBL] [Abstract][Full Text] [Related]
17. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
18. Global HIV-1 molecular epidemiology with special reference to genetic analysis of HIV-1 subtypes circulating in North India: functional and pathogenic implications of genetic variation.
Neogi U; Sood V; Banerjee S; Ghosh N; Verma S; Samrat S; Sharma Y; Saxena A; Husain S; Ramachandran VG; Das S; Sreedhar KV; Goel N; Wanchu A; Banerjea AC
Indian J Exp Biol; 2009 Jun; 47(6):424-31. PubMed ID: 19634706
[TBL] [Abstract][Full Text] [Related]
19. Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif.
Shao Q; Wang Y; Hildreth JE; Liu B
J Virol; 2010 May; 84(9):4840-4. PubMed ID: 20147392
[TBL] [Abstract][Full Text] [Related]
20. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.
Chen G; He Z; Wang T; Xu R; Yu XF
J Virol; 2009 Sep; 83(17):8674-82. PubMed ID: 19535450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
